Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 12/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25969977 | 0.88 | TRPA1 (0.53) | TRPA1MAPTTSHRNPBWR1RAB9A | |
| SCHEMBL25974095 | 0.86 | TRPA1 (0.55) | TRPA1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL25969531 | 0.86 | TRPA1 (0.52) | TRPA1MAPTTSHRNPBWR1RAB9A | |
| SCHEMBL25969533 | 0.85 | TRPA1 (0.47) | TRPA1MEN1KMT2A | |
| SCHEMBL25970867 | 0.84 | TRPA1 (0.53) | TRPA1MAPTRAB9AMEN1NPC1 | |
| SCHEMBL25969838 | 0.84 | TRPA1 (0.53) | TRPA1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL25969660 | 0.84 | TRPA1 (0.53) | TRPA1MAPTRAB9AMEN1NPC1 | |
| SCHEMBL25969052 | 0.84 | TRPA1 (0.53) | TRPA1MAPTNPBWR1RAB9ASMN1; SMN2 | |
| SCHEMBL25969149 | 0.82 | TRPA1 (0.52) | TRPA1MAPTRAB9AMEN1NPC1 | |
| SCHEMBL25969154 | 0.82 | TRPA1 (0.52) | TRPA1MAPTRAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154139-A1 | PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS | D. E. SHAW RESEARCH, LLC | 2025-05-15 | — | — | US | disclosed |
| WO-2023150591-A2 | PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS | D.E. SHAW RESEARCH, LLC (US) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154139-A1 | PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS | TRPA1, TRPV1, TRPV5 | TRPA1 1/4885MAPT 1001/4885TSHR 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.